| Pair Name | Gossypol, lenalidomide | ||
| Phytochemical Name | Gossypol (PubChem CID: 3503 ) | ||
| Anticancer drug Name | lenalidomide (PubChem CID: 216326 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Gossypol, lenalidomide | |||
| Disease Info | [ICD-11: 2A82] | Chronic lymphocytic leukemia | Investigative | |
| Gene Regulation | Down-regulation | Expression | BCL2 | hsa596 |
| Up-regulation | Phosphorylation | MAPK3 | hsa5595 | |
| Down-regulation | Expression | MCL1 | hsa4170 | |
| In Vitro Model | CII | Chronic lymphocytic leukemia | Homo sapiens (Human) | CVCL_0D73 |
| Result | Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner. Br J Haematol. 2012 Apr;157(1):59-66. doi: 10.1111/j.1365-2141.2011.08984.x. | Click |
